About Rivaara Labs
Rivaara Labs is a Healthcare company based in Mumbai (India) founded in 2019 by Bharat Daftary. PCR-based test kits are developed for pathogen detection in diagnostics. Rivaara Labs has raised $9.89 million across 2 funding rounds from investors including Kotak Mahindra Bank, Amicus Capital Partners and Bharat Daftary. The company has 143 employees. Rivaara Labs was last valued at $21.44 million in August 2023. Its chief executive, as recorded, is Rohit Seshadri. Its website rivaaralabs.com draws about 12 thousand monthly visits. Its Indian entity Rivaara Labs Private Limited reported revenue of ₹18.84 Cr. Rivaara Labs offers products and services including RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and HPV & LBC Panels. Its focus areas include Clinical Laboratory Chains and Pathology. Its competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Rivaara Labs was founded in 2019 and is based in Mumbai, India, within the molecular diagnostics sector. PCR-based test kits are developed by the company for detecting prevalent pathogens and supporting effective treatments. A network of specialized molecular diagnostics labs is being established, along with national reference labs. Novel point-of-care solutions are marketed to expand diagnostic access.
- Headquarters Mumbai, India
- Employees 143
- Founders Bharat Daftary
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rivaaralabs.com
- Social LinkedIn X Facebook Instagram
- Legal Name Rivaara Labs Private Limited
- Date of Incorporation 18 Oct, 2019
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹18.84 Cr
FY 2026 · -26% YoY
- Net Loss-₹17.30 Cr
FY 2026 · -92% margin
- EBITDA-₹12.98 Cr
FY 2026 · -69% margin
- Total Equity Funding$9.89M (USD)
in 2 rounds
- Latest Funding Round$2.59M (USD), Series A
Aug 2023
- InvestorsKotak Mahindra Bank
& 2 more
- Employee Count143
Associated legal entities of Rivaara Labs
Rivaara Labs operates through Rivaara Labs Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Rivaara Labs Private Limited CIN U85300MH2019PTC331867 | Active | 18 Oct 2019 | Mumbai, Maharashtra | ₹18.8 Cr | 143 | 3 | View details |
Products & Services of Rivaara Labs
Rivaara Labs offers a comprehensive portfolio of products and services, including RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and HPV & LBC Panels.
Tests for respiratory infections and pathogens
Detects sepsis-related bacteria and fungi
Identifies meningitis and encephalitis pathogens
Screens for tuberculosis and drug resistance
Detects human papillomavirus and related conditions
Provides tests for cancer detection and monitoring
Funding Insights of Rivaara Labs
Rivaara Labs has successfully raised a total of $9.89M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.59 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.89M
- Total Rounds 2
- Last Round Series A — $2.59M
- First Round $7.3M
(Oct 2022)
- Investors Count 3
All 2 funding rounds of Rivaara Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $2.59M | Series A | $21.44M | – | |
| Oct 2022 | $7.3M | Series A | $17.37M | Amicus Capital Partners, Kotak Mahindra Bank |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2023 | $21.44M | •••••••• |
| Oct 2022 | $17.37M | •••••••• |
Last known valuation $21.44M (Aug 2023). 3 investors in total: 2 institutional and 1 angel.
Investors in Rivaara Labs
Rivaara Labs has secured backing from 3 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Amicus Capital Partners and Bharat Daftary.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment services in financial services, consumer, healthcare, technology, and manufacturing sectors. | 2015 | amicuscapital.in | Bengaluru, India | |
Commercial banking services are offered to corporate and retail customers. | 1985 | kotak.com | Mumbai, India | |
BD Bharat Daftary | unknown_a910d1a13f7b4f15b |
Investor details for Rivaara Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Rivaara Labs Private Limited (Rivaara Labs)
Rivaara Labs Private Limited is the primary company behind Rivaara Labs. The board of Rivaara Labs Private Limited currently have 2 directors; the longest-serving is Divy Dangi, appointed in 2025. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Divy Dangi DIN 08323807 | Nominee Director | 31 Oct 2025 | 1 yr | Rivaara Labs Private Limited |
| Dominik Benjamin Vonier DIN 11397572 | Nominee Director | 07 Oct 2026 | Rivaara Labs Private Limited |
People of Rivaara Labs
21 people are tracked at Rivaara Labs (6 in leadership, 15 in team); the tracked headcount is 143.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Rohit Seshadri | CEO | Leadership |
Dr. Girish Gaur | Associate Director - Lab Operations (Pan India) | Leadership |
Dhruba Jyoti Sarma, PhD | Head of Laboratory | Leadership |
Dr. Shafeeq Hassan A | Cluster Head | Leadership |
Tom Darlington | Director Strategy And Corporate Development | Leadership |
Dipashree Patil | Senior Scientific Officer | Team |
Nisha Pal | Lead Research Scientist | Team |
Jignasa Tank | Area Sales Manager | Team |
yuvakishore Nagavalli | Area Sales Manager | Team |
Dr. Gajula Hari | Cluster Lab Manager (South) | Team |
Radhakrishnan Venkatesan | Cluster Lab Manager | Team |
Gayathri K V | Research Associate | Team |
Monika Gandhi | Research Associate | Team |
Sooraj Babu S | Research Associate | Team |
Harris Bala | Application Engineer | Team |
Jayprakash Prajapati | Senior Scientific Officer | Team |
Suraj Kawale | Information Technology Manager | Team |
RENJISH R. SHENOY | Regional Business Manager | Team |
Ritu Pandey | Research Associate | Team |
1 more people are available in the full profile.
Complete people profiles for Rivaara Labs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Rivaara Labs
Figures of Rivaara Labs Private Limited, the primary company behind Rivaara Labs, for FY 2026. Revenue was ₹18.84 Cr (-26% year on year). Net loss was -₹17.30 Cr (-92% margin). EBITDA was -₹12.98 Cr (-69% margin). Revenue has grown at a compounded annual rate of -7% over three years and +31% over five years.
- ₹18.84 CrRevenue · FY 2026 · -26% YoY
- -₹17.30 CrNet loss · -92% margin
- -₹12.98 CrEBITDA · -69% margin
- ₹122 CrPaid-up capital
- 143Employees (provident fund records)
- -7%Revenue CAGR, 3 years
- +31%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Rivaara Labs Private Limited are on its company page.
Detailed financial statements for Rivaara Labs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Rivaara Labs
4 dated milestones of Rivaara Labs across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Rivaara Labs is founded.
- Funding First funding round of $7.3M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $2.6M.
Competitors of Rivaara Labs
Rivaara Labs has 3 listed competitors in our database, 3 of them funded. They include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lalpathlabs.com | 1949 | Gurugram, India | $13.9M | 8,279 | Chain of pathology and radiology labs | |
| redcliffelabs.com | 2018 | Noida, India | $116.42M | 2,104 | Home-based diagnostic tests are booked via an online platform. | |
| sterlingaccuris.com | 2015 | Ahmedabad, India | $41.69M | 1,229 | Pathology diagnostic services are offered via a chain of labs. |
Detailed competitors of Rivaara Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rivaara Labs
The website of Rivaara Labs (rivaaralabs.com) receives about 12.2K visits a month.
- Monthly visits12.2K
▼ 44% vs previous month
Top companies in Diagnostics Laboratories
3 companies that operate in the same segment as Rivaara Labs (Diagnostics Laboratories) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic testing centers for pathology and health screenings are operated. | 1996 | Mumbai, Maharashtra, India | USD 63.59 M | USD 88.36 M | 1,950 | |
Chain of pathology and radiology labs | 1949 | Gurugram, Haryana, India | USD 13.9 M | USD 294.49 M | 5,310 | |
Home-based diagnostic tests are booked via an online platform. | 2018 | Noida, Uttar Pradesh, India | USD 116.42 M | USD 41.86 M | 2,308 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rivaara Labs
Complete news archive for Rivaara Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rivaara Labs
Rivaara Labs was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Rivaara Labs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Rohit Seshadri is the CEO of Rivaara Labs, as recorded in our data.
Rivaara Labs is a funded company, having raised a total of $9.89M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.3M, raised on Oct 2022.
Rivaara Labs has 143 employees.
The primary company behind Rivaara Labs, Rivaara Labs Private Limited, reported revenue of ₹18.84 Cr for FY 2026, down 26% year on year.
Rivaara Labs was founded in 2019 and is based in Mumbai, India, within the molecular diagnostics sector. PCR-based test kits are developed by the company for detecting prevalent pathogens and supporting effective treatments. A network of specialized molecular diagnostics labs is being established, along with national reference labs. Novel point-of-care solutions are marketed to expand diagnostic access.
Rivaara Labs's top competitors include Dr Lal PathLabs, Redcliffe Labs and Sterling Accuris Diagnostics.
Rivaara Labs offers RespiQuik Panels, SeptiQuik Panels, MeningoQuik Panels, Tuberculosis Panels, and 2 more products and services.
Rivaara Labs has 3 investors. Key investors include Kotak Mahindra Bank, Amicus Capital Partners, and Bharat Daftary.
The valuation of Rivaara Labs is $21.44M as of Aug 2023.
Rivaara Labs operates through Rivaara Labs Private Limited.